Related Experiment Video
Updated: Jun 26, 2026

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva
Published on: January 12, 2019
Volume-Stable Collagen Matrix With or Without Platelet-Rich Fibrin Impregnation for Multiple Gingival Recessions: A
Gabriel Leonardo Magrin1, Roberta Michels1,2, Ana Clara Kuerten Gil1
1Centre for Education and Research on Dental Implants (CEPID), Department of Dentistry, Federal University of Santa Catarina (UFSC), Florianópolis, Brazil.
Aim:
This split-mouth randomized clinical trial aimed to assess whether incorporating platelet-rich fibrin (PRF) into a volume-stable collagen matrix results in superior reduction of recession depth after 6 months of healing in the treatment of multiple gingival recessions using the coronally advanced flap.
Methods:
Patients with bilateral maxillary RT1 recessions at non-molar sites were recruited. Each side received either a PRF-impregnated matrix or a non-impregnated matrix. Clinical parameters, including recession depth, keratinized tissue width, bleeding on probing, probing depth, clinical attachment level, and gingival thickness, were measured at baseline and 6 months, as well as the Root Coverage Esthetic Score (RES) and patient-reported outcome measures (PROMs). The percentage of complete root coverage was calculated 6 months after treatment.
Results:
Twenty-five patients were enrolled. However, one patient was excluded due to incomplete follow-up. Both groups significantly improved over time, but no intergroup differences were observed for any of the clinical parameters (p > 0.05). No statistically significant differences were found between test and control groups in evaluations of RES and PROMs, showing similar postoperative experiences of patients.
Conclusion:
Within the limitations of this study, adding PRF to a volume-stable collagen matrix did not result in superior recession depth reduction or improved clinical, esthetic, or patient-reported outcomes after 6 months.
Trial Registration:
Brazilian Register of Clinical Trials (ensaiosclinicos.gov.br) identifier: RBR-3hqrvrr (20/10/2021).